Why the study?
Does the addition of omega-3 fatty acids to atorvastatin improve TG and non-HDL-C levels in patients with residual hypertriglyceridemia?
Does the addition of omega-3 fatty acids to atorvastatin improve TG and non-HDL-C levels in patients with residual hypertriglyceridemia?
Adding omega-3 fatty acids to atorvastatin significantly improves triglyceride and non-HDL cholesterol levels in patients with residual hypertriglyceridemia.
Supports adjunctive OM3-FAs with atorvastatin in residual hypertriglyceridemia; extends limited RCT evidence on TG/non-HDL-C.
The addition of OM3-FAs to atorvastatin improved TG and non-HDL-C levels to a significant extent compared to atorvastatin alone in subjects with residual hypertriglyceridemia.
No takes yet. Share an insight, caveat, or question.
Jun et al. (2019) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: